Literature DB >> 30082453

Molecular Pathology of High-Grade Prostatic Intraepithelial Neoplasia: Challenges and Opportunities.

Levent Trabzonlu1, Ibrahim Kulac2, Qizhi Zheng1, Jessica L Hicks1, Michael C Haffner1,3, William G Nelson1,3,4, Karen S Sfanos1,3,4, Onur Ertunc1, Tamara L Lotan1,3, Christopher M Heaphy1,3,4, Alan K Meeker1,3,4, Srinivasan Yegnasubramanian3,4, Angelo M De Marzo1,3,4.   

Abstract

A better understanding of the early stages of prostate cancer initiation, potentially arising from precursor lesions, may fuel development of powerful approaches for prostate cancer prevention or interception. The best-known candidate for such a precursor lesion has been referred to as high-grade prostatic intraepithelial neoplasia (HGPIN). Although there is significant evidence supporting the notion that such HGPIN lesions can give rise to invasive adenocarcinomas of the prostate, there are also numerous complicating considerations and evidence that cloud the picture in many instances. Notably, recent evidence has suggested that some fraction of such lesions that are morphologically consistent with HGPIN may actually be invasive carcinomas masquerading as HGPIN-a state that we term "postinvasive intraepithelial carcinoma" (PIC). Although the prevalence of such PIC lesions is not fully understood, this and other factors can confound the potential of identifying prostate precursors that can be targeted for disease prevention, interception, or treatment. Here, we review our current understanding of the morphological and molecular pathological features of prostate cancer precursor lesions.
Copyright © 2019 Cold Spring Harbor Laboratory Press; all rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 30082453      PMCID: PMC6444695          DOI: 10.1101/cshperspect.a030403

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN: 2157-1422            Impact factor:   6.915


  115 in total

1.  Evidence of multifocality of telomere erosion in high-grade prostatic intraepithelial neoplasia (HPIN) and concurrent carcinoma.

Authors:  Bisera Vukovic; Paul C Park; Jaudah Al-Maghrabi; Ben Beheshti; Joan Sweet; Andy Evans; John Trachtenberg; Jeremy Squire
Journal:  Oncogene       Date:  2003-04-03       Impact factor: 9.867

2.  More than just proliferation: Myc function in stem cells.

Authors:  Mark J Murphy; Anne Wilson; Andreas Trumpp
Journal:  Trends Cell Biol       Date:  2005-03       Impact factor: 20.808

3.  BET bromodomain inhibition as a therapeutic strategy to target c-Myc.

Authors:  Jake E Delmore; Ghayas C Issa; Madeleine E Lemieux; Peter B Rahl; Junwei Shi; Hannah M Jacobs; Efstathios Kastritis; Timothy Gilpatrick; Ronald M Paranal; Jun Qi; Marta Chesi; Anna C Schinzel; Michael R McKeown; Timothy P Heffernan; Christopher R Vakoc; P Leif Bergsagel; Irene M Ghobrial; Paul G Richardson; Richard A Young; William C Hahn; Kenneth C Anderson; Andrew L Kung; James E Bradner; Constantine S Mitsiades
Journal:  Cell       Date:  2011-09-01       Impact factor: 41.582

4.  Current or recent smoking is associated with more variable telomere length in prostate stromal cells and prostate cancer cells.

Authors:  Corinne E Joshu; Sarah B Peskoe; Christopher M Heaphy; Stacey A Kenfield; Lorelei A Mucci; Edward L Giovannucci; Meir J Stampfer; Ghilsuk Yoon; Thomas K Lee; Jessica L Hicks; Angelo M De Marzo; Alan K Meeker; Elizabeth A Platz
Journal:  Prostate       Date:  2017-11-22       Impact factor: 4.104

Review 5.  Clinical implications of PTEN loss in prostate cancer.

Authors:  Tamara Jamaspishvili; David M Berman; Ashley E Ross; Howard I Scher; Angelo M De Marzo; Jeremy A Squire; Tamara L Lotan
Journal:  Nat Rev Urol       Date:  2018-02-20       Impact factor: 14.432

6.  Targeting MYC Expression through G-Quadruplexes.

Authors:  Tracy A Brooks; Laurence H Hurley
Journal:  Genes Cancer       Date:  2010-06

Review 7.  Inflammation in prostate carcinogenesis.

Authors:  Angelo M De Marzo; Elizabeth A Platz; Siobhan Sutcliffe; Jianfeng Xu; Henrik Grönberg; Charles G Drake; Yasutomo Nakai; William B Isaacs; William G Nelson
Journal:  Nat Rev Cancer       Date:  2007-04       Impact factor: 60.716

8.  Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis.

Authors:  W H Lee; R A Morton; J I Epstein; J D Brooks; P A Campbell; G S Bova; W S Hsieh; W B Isaacs; W G Nelson
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-22       Impact factor: 11.205

9.  Telomerase activity: a prevalent marker of malignant human prostate tissue.

Authors:  H J Sommerfeld; A K Meeker; M A Piatyszek; G S Bova; J W Shay; D S Coffey
Journal:  Cancer Res       Date:  1996-01-01       Impact factor: 12.701

Review 10.  GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer.

Authors:  Masashi Nakayama; Mark L Gonzalgo; Srinivasan Yegnasubramanian; Xiaohui Lin; Angelo M De Marzo; William G Nelson
Journal:  J Cell Biochem       Date:  2004-02-15       Impact factor: 4.429

View more
  6 in total

Review 1.  Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Medicines (Basel)       Date:  2019-07-30

2.  Cancer Progress and Priorities: Prostate Cancer.

Authors:  Kevin H Kensler; Timothy R Rebbeck
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-02       Impact factor: 4.254

3.  An in Situ Atlas of Mitochondrial DNA in Mammalian Tissues Reveals High Content in Stem and Proliferative Compartments.

Authors:  Jiayu Chen; Qizhi Zheng; Lauren B Peiffer; Jessica L Hicks; Michael C Haffner; Avi Z Rosenberg; Moshe Levi; Xiaoxin X Wang; Busra Ozbek; Javier Baena-Del Valle; Srinivasan Yegnasubramanian; Angelo M De Marzo
Journal:  Am J Pathol       Date:  2020-04-15       Impact factor: 4.307

4.  GSTP1 positive prostatic adenocarcinomas are more common in Black than White men in the United States.

Authors:  Igor Vidal; Qizhi Zheng; Jessica L Hicks; Jiayu Chen; Elizabeth A Platz; Bruce J Trock; Ibrahim Kulac; Javier A Baena-Del Valle; Karen S Sfanos; Sarah Ernst; Tracy Jones; Janielle P Maynard; Stephanie A Glavaris; William G Nelson; Srinivasan Yegnasubramanian; Angelo M De Marzo
Journal:  PLoS One       Date:  2021-06-30       Impact factor: 3.240

5.  A MYC and RAS co-activation signature in localized prostate cancer drives bone metastasis and castration resistance.

Authors:  Juan M Arriaga; Sukanya Panja; Mohammed Alshalalfa; Junfei Zhao; Min Zou; Arianna Giacobbe; Chioma J Madubata; Jaime Yeji Kim; Antonio Rodriguez; Ilsa Coleman; Renu K Virk; Hanina Hibshoosh; Onur Ertunc; Büşra Ozbek; Julia Fountain; R Jeffrey Karnes; Jun Luo; Emmanuel S Antonarakis; Peter S Nelson; Felix Y Feng; Mark A Rubin; Angelo M De Marzo; Raul Rabadan; Peter A Sims; Antonina Mitrofanova; Cory Abate-Shen
Journal:  Nat Cancer       Date:  2020-10-19

Review 6.  If this is true, what does it imply? How end-user antibody validation facilitates insights into biology and disease.

Authors:  Karen S Sfanos; Srinivasan Yegnasubramanian; William G Nelson; Tamara L Lotan; Ibrahim Kulac; Jessica L Hicks; Qizhi Zheng; Charles J Bieberich; Michael C Haffner; Angelo M De Marzo
Journal:  Asian J Urol       Date:  2018-12-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.